Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003720 · ClinicalTrials.gov registry record · Phase 1
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003720: Completed Phase 1 study, sponsored by Pfizer.
NCT00003720 is a Phase 1 study that has completed, run by Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003720, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
Interventions
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-07 |
| Phase | Phase 1 |
What the finished NCT00003720 record still lists
NCT00003720 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which semaxanib is the first listed.
NCT00003720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003720 about?
NCT00003720 is a clinical study titled "SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma". RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
What is the current status of trial NCT00003720?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-07.
What interventions are being tested in trial NCT00003720?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00003720?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia